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Abstract 
A fundamental goal of many surgeries is nerve preservation, as inadvertent injury can lead to patient 
morbidity including numbness, pain, localized paralysis and incontinence. Nerve identification during 
surgery relies on multiple parameters including anatomy, texture, color and relationship to 
surrounding structures using white light illumination. We propose that fluorescent labeling of nerves 
can enhance the contrast between nerves and adjacent tissue during surgery which may lead to 
improved outcomes. 
Methods: Nerve binding peptide sequences including HNP401 were identified by phage display 
using selective binding to dissected nerve tissue. Peptide dye conjugates including FAM-HNP401 and 
structural variants were synthesized and screened for nerve binding after topical application on 
fresh rodent and human tissue and in-vivo after systemic IV administration into both mice and rats. 
Nerve to muscle contrast was quantified by measuring fluorescent intensity after topical or systemic 
administration of peptide dye conjugate.  
Results: Peptide dye conjugate FAM-HNP401 showed selective binding to human sural nerve with 
10.9x fluorescence signal intensity (1374.44 ± 425.96) compared to a previously identified peptide 
FAM-NP41 (126.17 ± 61.03). FAM-HNP401 showed nerve-to-muscle contrast of 3.03 ± 0.57. 
FAM-HNP401 binds and highlight multiple human peripheral nerves including lower leg sural, upper 
arm medial antebrachial as well as autonomic nerves isolated from human prostate.  
Conclusion: Phage display has identified a novel peptide that selectively binds to ex-vivo human 
nerves and in-vivo using rodent models. FAM-HNP401 or an optimized variant could be translated 
for use in a clinical setting for intraoperative identification of human nerves to improve visualization 
and potentially decrease the incidence of intra-surgical nerve injury. 
Key words: human nerve, fluorescence imaging, nerve targeting, translational 
Introduction 
A fundamental goal of surgery is preservation of 
nerve function to minimize patient morbidity. 
Current nerve identification during surgery utilizes 
non-quantifiable criteria such as anatomy, texture, 
color and relationship to surrounding structures. In 
instances of trauma, tumor invasion or infection, 
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nerve identification using the above criteria can be 
even more challenging. Using white light reflectance, 
the visual difference between nerves, especially small 
nerves like the autonomic nerves within the prostate, 
and adjacent tissue can be imperceptible. Inadvertent 
injury to these thin or buried nerves is one of the most 
morbid but unintended consequences of surgery, 
which can lead to loss of function, numbness, and 
surgery induced neuropathic pain [1]. For example, 
radical prostatectomy (RP) can be performed for 
localized prostate cancer with excellent locoregional 
control [2, 3]. However, even with nerve-preserving 
radical prostatectomy there is a significant risk of 
erectile dysfunction and/or urinary incontinence, due 
to inadvertent injury to autonomic nerves or the 
autonomic neurovascular bundles [4, 5]. Preservation 
of the autonomic neurovascular bundles along the 
posterolateral aspect of the prostate is an important 
aspect for functional preservation during RP. The 
autonomic nerve fibers themselves are rarely 
visualized, but rather their position is presumed to 
track along vascular structures. The exact position and 
distribution of these autonomic nerves are variable 
from patient to patient, complicating the use of 
anatomical location as the sole method of avoidance 
[6-8] and injury can occur even in the most 
experienced hands. Recent studies showed that only 
7% of RP patients regained pre-surgical state of full 
erectile function in the first year [9] and 16% regained 
baseline erectile function 2 years after prostatectomy 
[10].  
Tools to improve visualization of the neural 
structures in the prostate have great potential for 
reducing morbidity from radical prostatectomy, as 
well as applications in many other nerve-preserving 
surgeries including cancer resection, trauma and 
reconstructive procedures. Systemic administration of 
a nerve imaging agent could allow the labeling of all 
relevant nerves with a single probe administration. 
Previously, reported methods rely on retrograde or 
anterograde tracing of individually axonal tracts by 
direct application of fluorescent dyes to the 
innervation site [11, 12]. Styryl pyridinium dyes 
[13-15], aminostyryl dyes [16-18], oxazine 4 [19, 20], 
and anti-ganglioside antibodies [21] have been 
investigated in various preclinical models to detect 
motor, sensory and autonomic nerves.  
We previously identified a peptide sequence, 
Nerve Peptide 41 (NP41), through phage display that 
preferentially binds and highlights peripheral nerve 
tissue, enhancing visualization of motor and sensory 
nerves in live mice after systemic injection [22-24]. 
This peptide has relatively low affinity for nerve and 
rapid blood clearance (compared to antibodies) so it 
can be visualized a few hours after systemic injection 
with almost complete wash-out by 24 h [22]. NP41 has 
also been shown to highlight degenerate nerves 
through binding to structural laminins in nerve fibers 
[24, 25]. We have now used this peptide for 
intraoperative identification of autonomic nerves in 
the prostate of both mice and rats. To allow clinical 
translation of nerve visualization methods for use in 
surgeries involving human patients, we have now 
used phage display to identify a novel peptide 
HNP401 that, when labeled with a fluorophore, 
selectively binds and highlights human nerves. We 
show that fluorescently labeled HNP401 can bind to 
and highlight human sensory and motor nerves such 
as sural, medial antebrachial cutaneous, laryngeal, 
ansa cervicalis, great auricular nerve and autonomic 
nerves like those within and around the prostate 
gland.  
Results  
To visualize the autonomic nerves within the 
prostate of mice, we injected NP41 peptide conjugated 
to fluorescein (FAM-NP41) intravenously followed by 
imaging of prostate and surrounding tissue after 
surgical resection. Strong fluorescence from dye that 
rapidly accumulates in the bladder hindered 
visualization of the nerves within the prostate. To 
enhance visualization the bladder was surgically 
drained of urine and sutured prior to imaging. The 
urethra, an anatomically distinct structure, is never 
emptied of urine as the mice are alive for the duration 
of the experiment, resulting in a continuous passage 
of urine carrying metabolized peptide-dye to the 
bladder via the urethra. To aid future research, we 
have demonstrated using a fluorescence quenching 
dye (both directly injected in the bladder and through 
oral administration) to reduce high bladder 
fluorescence, as an alternative to surgical draining of 
the bladder (Figure S1). FAM-NP41 was injected at 
doses ranging from 150-600 nmol (~16-66 mg/kg) 
with a 600 nmol (~30 nmol/g) dose showing optimal 
autonomic nerve contrast (Figure 1). Low magnifi-
cation fluorescence imaging shows highlighting of a 
single nerve fiber running adjacent to the urethra 
(Figure 1A). The nerve is extremely faint in a high 
magnification image using white light reflectance 
(Figure 1B) but becomes distinctly visible with 
FAM-NP41 labeling (Figure 1C). To quantify nerve 
detection, a total of 10 mice were injected with 600 
nmol FAM-NP41 and signal intensity was measured 
for nerve versus adjacent non-nerve tissue using both 
fluorescence and white light reflectance. Values to the 
right of the line indicate that there is improved 
visualization with fluorescence compared to reflected 
light. Average nerve to non-nerve signal intensity 
with fluorescence guidance was 1.256 ± 0.14 (n=12, 
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p<0.001) compared to 1.086 ± 0.07 (n= 12) for 
white-light reflectance (Figure 1D). 
Because prostate nerves in mice were very small 
and challenging to image (i.e., requiring a high dose 
of FAM-NP41) we extended our study to the 
visualization of autonomic nerves within the prostate 
of rats. To visualize autonomic nerves in male 
Sprague Dawley rats, FAM-NP41 was injected 
intravenously at a dose of 12 nmol/g, followed by 
imaging. This is a 2.5x lower dose relative to weight 
compared to the 600 nmol used in 20 g mice. Useful 
labeling occurred 2-6 h after intravenous 
administration, which was visualized using a 
customized fluorescence dissecting microscope. 
FAM-NP41 nerve highlighting enables visualization 
of nerve fibers running through the middle of the rat 
prostate (Figure 1E). Higher magnification imaging 
showed that FAM-NP41 additionally highlighted 
autonomic nerve branches surrounding the 
neurovascular bundle (Figure 1G), which travel 
within the fatty capsule of the prostate gland. These 
branching nerves were not visible using white light 
reflectance imaging (Figure 1F). To quantitate 
selective labeling of autonomic nerves in rats, nerves 
within the prostate gland were imaged with both 
fluorescence and white light reflectance. Average 
nerve to non-nerve signal intensity from fluorescence 
was 1.275 ± 0.02 (n=3) compared to 1.083 ± 0.01 (n=3) 
for white light reflectance. To show applicability to 
intra-surgical imaging, we show that similar nerve 
contrast was observed in live rats using a clinical 
grade Zeiss Pentero imaging system (Figure 1H). The 
Zeiss Pentero scope, which is approved for clinical 
use, overlays the fluorescence image from FAM-NP41 
(yellow) on the white light image with data collection 
in real time (Figure 1H). Recordings during surgical 
manipulation show fluorescent fibers within the 
prostate that clearly present as nerves that are 
detectable using NP41-FAM fluorescence guidance 
(Video S1). To confirm that the fluorescently labelled 
structures were indeed nerves, fluorescence surgical 
guidance was used in real time to selectively dissect 
out fluorescent fibers that were thought to be nerves 
(Figure S2A). Dissected fluorescent fibers were then 
positioned vertically and flash frozen in OCT 
embedding compound. Vertical cross sections were 
imaged using fluorescence to show that suspected 
nerve fibers were centered on slides (Figure S2B). 
Fibers were confirmed to be nerve as they were 
fluorescently labelled using dual immunohisto-
chemically analysis with antibodies against either 
fluorophore (Figure S2C) or tyrosine hydroxylase 
(Figure S2D), a known marker for unmyelinated 
autonomic nerves. No immunostaining was detected 
in the absence of primary antibody (Figure S2E) 
To enable translation of a nerve-illumination 
peptide for use in human patients, we performed 
phage display to identify human nerve-binding 
peptides using an m13 phage library expressing 16 
random amino acid sequences on the N-terminus of 
gIII (Creative Biolabs). Phage were selected using 
iterative rounds of selection for binding to human 
sural nerve with negative selection to muscle and fat. 
Counter selection to muscles and fat was done by 
pre-absorbing the library with these tissues prior to 
selection for binding to human nerve. Individual 
phage were sequenced after each round of selection 
and three specific sequences, SGQVPWEEPYYVVKKS 
 
Figure 1. In-vivo fluorescent labelling of autonomic nerves in rodents. (A) Low magnification fluorescence image showing bladder, vas deferens and urethra running 
through the prostate with adjacent autonomic nerve labeled with FAM-NP41 in mice. Higher magnification white light reflectance image (B) and corresponding fluorescence 
grayscale image (C) of the autonomic nerve running adjacent to the urethra. Quantitation of autonomic nerve detection by fluorescence compared to white light detection in 
mice (D). Nerve-to-muscle contrast for reflectance/fluorescence were plotted for individual nerve branches. Values to the right of the line indicate that there is improved 
visualization with fluorescence compared to reflected light. Images (E-G) are analogous to (A-C) except that they highlight FAM-NP41-dependent labeling of autonomic nerve 
in rat prostate versus mouse, with white light imaging showing non-visible nerve (F). (H) FAM-NP41-labeled prostate nerve is also detectable using a clinical grade Zeiss Pentero 
Surgical Microscope. 
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(HNP401), WEYHYVDLNWTSQHPQ (HNP402), and 
DLPDIIWDFNWETAG (HNP403), were highly 
enriched after 5 and 6 rounds.  
To test the affinity of the selected phage display 
peptides for binding to human nerves, they were 
chemically synthesized by solid-phase synthesis and 
labeled with fluorescein. Peptides were topically 
applied to sections of surgically harvested human 
sural nerve and temporalis muscle to determine 
nerve-to-muscle contrast for selected peptides and 
controls (Figure S3). Controls including free dye 
(carboxyfluorescein) were also tested on various 
nerves from multiple patient tissues to confirm 
specificity of peptide-dye conjugates for binding 
human nerve (Figure S4). We have shown that free 
non-reactive dye controls such as carboxyfluorescein 
show only weak non-specific binding and are not 
efficacious for topical applications. FAM-HNP401 
yielded the highest contrast and was shown to be 
superior to the previously reported rodent nerve 
binding peptide FAM-NP41[22], when topically 
applied to human sural nerve (Figure 2). To quantify 
differential binding to nerve versus muscle, 
fluorescence signal intensity was measured for ROIs 
from the perineurium of select nerves and human 
temporalis muscle. FAM-HNP401 showed selective 
binding to human sural nerve with 10.9x fluorescence 
signal intensity (1374.44 ± 425.96) compared to 
FAM-NP41 (126.17 ± 61.03) (Figure 2D, p=0.009, 
Student’s t-test, unpaired). Nerve-to-muscle contrast 
was comparable at 3.03 ± 0.57 for FAM-HNP401 and 
2.28 ± 0.96 for FAM-NP41 (Figure 2H, p=0.236, 
Student’s t-test, unpaired).  
FAM-HNP401 was also tested topically on 
ex-vivo tissue for labeling mouse facial nerve with 
surrounding muscle, where it did not perform as well 
as FAM-NP41 (Figure S5J-M). For comparison, 
ex-vivo tissue labeling of human laryngeal nerve with 
surrounding muscle with FAM-NP41 and 
FAM-HNP401 is shown (Figure S5F-I). Autofluores-
cence of human nerve without treatment of 
peptide-dye conjugate was negligible compared to the 
signal intensity acquired after topical application of 
FAM-HNP401 (Figure S6). FAM-HNP401 also has a 
2.3x higher signal intensity for in-vivo binding to 
mouse sciatic nerve compared to FAM-NP41 (Figure 
3A-C). Nerve to surrounding muscle contrast was 
comparable for the two peptides (Figure 3D). 
FAM-HNP401 also highlighted rat sciatic nerve 
(Figure 3E) and prostate nerve (Figure 3F) at a dose of 
2 µmol (~54 mg/kg) when imaged 3 h post injection. 
The bladder was drained with a syringe and sutured 
to avoid spillage and contamination around the 
prostate. The collected urine was analyzed by mass 
spectrometry and expected fragments of the peptide 
with dye attached were detected, indicating peptide 
in bladder was partially metabolized (Figure S7). 
Autonomic nerves within the prostate and adjacent to 
the vascular bundle could be easily visualized when 
imaged at higher magnification using a dose of 0.5 
 
 
Figure 2. Comparison of FAM-HNP401 and FAM-NP41 in binding and labelling of human sural nerve. Topical application of 100 µM of FAM-HNP401 on 10 µm 
sections of unfixed human sural nerve tissue (A) and human temporalis muscle tissue (E) kept adjacent on the same glass slide and imaged on a confocal microscope with 488 
nm laser excitation. For comparison, FAM-NP41 was applied to a sequential section of human nerve (B) and muscle (F) under identical conditions as for (A, E). H&E staining of 
the nerve (C) and muscle (G). (D) Signal intensity of perineurium of nerve tissue treated with FAM-HNP401 (n=4) compared with FAM-NP41 (n=4). (H) Nerve-to-muscle 
contrast of peptides applied topically to human tissue sections (n=4). 
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µmol (13.4 mg/kg) FAM-HNP401 10 min after probe 
injection (Figure 3G). Blood clearance of 
FAM-HNP401 showed a half-life of 30 min, which is 
similar to FAM-NP41 (Figure 3H). Optimal nerve 
contrast was detected using 50-100 µM (Figure S5A-E) 
with low concentration (10 µM) high resolution 
confocal imaging showing that FAM-HNP401 binds 
with high affinity to perineurium, epineurium and 
endoneurium while being excluded from axons 
(Figure S5N). FAM-HNP401 signal from human 
nerve saturates at 100 µM, while the signal from 
FAM-NP41 continues to increase even at 375 µM, but 
the signal intensity remains much lower than that of 
HNP401 applied at the same concentration (Figure 
S5F-H). The stability of FAM-HNP401 in human 
plasma at 5 min and 2 h was determined by 
incubation of the peptide-dye conjugate in human 
serum prior to analysis by mass spectrometry. For 
analysis, the area-under-the-curve at 450 nm and the 
corresponding mass of FAM-HNP401 were 
determined after injection of a fixed volume of analyte 
into the LC-MS (Figure S8A-B). For comparison, we 
also tested the stability of FAM-NP41 in human 
plasma (Figure S7C-D). Integration of the peak area at 
5 min and 2 h indicates that both FAM-HNP401 and 
FAM-NP41 were stable in human serum. The area of 
extracted ion-current was used to determine peptide 
quantitation. No degradation of peptide-FAM 
conjugate was observed, with identical concentration 
detected at 5 min and 2 h of incubation with human 
plasma from analysis of the ion current. Peptides were 
analogously tested and shown to be stable in rat 
cerebrospinal fluid following 2 h exposure (Figure 
S8E-F).  
FAM-HNP401 and FAM-NP41 were tested for 
binding to autonomic nerves, isolated from the 
prostate glands of two human patients (Figure 4 and 
Figure S9). FAM-HNP401 (Figure 4A and Figure 
S9A) showed a significantly higher fluorescence 
signal in autonomic (cavernosal) nerves compared to 
FAM-NP41 (Figure 4B and Figure S9B). Quantitation 
was not done because only 2 patient samples were 
available for testing, as nerve resection during radical 
prostatectomy is only performed in instances of gross 
capsular invasion. Labelled fibers were confirmed as 
nerve using anti-neurofilament antibody SMI312 (red) 
with DAPI (blue) to show nuclear labeling (Figure 
4C). H&E staining also confirmed the labeled tissue as 
nerve by histology (Figure 4D). SMI312 does not stain 
perineurium due to the lack of neurofilament fibers in 
this region of the nerve bundle. SMI312 staining 
shows that the tissue isolated is nerve due to staining 
of neurofilament structures that support the axons. 
Similar staining using FAM-HNP401 was obtained for 
another sensory nerve (anti-brachial cutaneous) 
isolated from human arm, showing the broad 
nerve-binding activity of HNP401 (Figure 4E-H).  
To optimize and attempt to determine the core 
binding domain of HNP401, we performed systematic 
deletion of two amino acids from the C or N terminus 
(Table S1) followed by binding analysis on human 
sural nerve sections (Figure 5). In each case, nerve 
 
Figure 3. In vivo imaging of nerve-binding peptides in mice and rats with pharmacokinetics. In-vivo fluorescence images of sciatic nerves from 6-month-old SKH1 
mice that had been previously intravenously injected with 450 nmol of FAM-HNP401 (~48.4 mg/kg) (A) or FAM-NP41 (~39 mg/kg) (B). (C) The fluorescence intensity of the 
sciatic nerve measured and quantitated in Image J showed a 2.3-fold increase for FAM-HNP401 compared to FAM-NP41. (D) Nerve-to-muscle contrast for the two peptides 
were comparable at 5.79 ± 0.81 for FAM-HNP401 and 6.63 ± 1.63 for FAM-NP41. (E) In vivo fluorescence image of rat sciatic nerve 5 h after intravenous injection of 2 µmol of 
FAM-HNP401 (~54 mg/kg). Rat prostate nerve imaged with a real-time custom surgical imaging system (F) and Lumar small animal microscope (G) 5 h after intravenous injection 
of 2 µmol of FAM-HNP401. (H) The blood clearance curve shows FAM signal obtained from equal volume blood draws taken from five SKH1-Elite male mice. Each mouse was 
injected intravenously with 100 nmol (~11 mg/kg) of FAM-HNP401 prior to blood collection at 1 min, 10 min, 20 min, 30 min, 1 h and 2 h time points. 
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binding and signal intensity was normalized to the 
parent FAM-HNP401 peptide (Figure 5J). Removal of 
the C-terminal serine (C-2) was tolerated, but upon 
removal of lysine (C-4) the solubility and binding was 
reduced dramatically with a normalized average 
signal intensity of 0.49 ± 0.11 for nerve binding of 
HNP401-C-4 (Figure 5F). Deletion of amino acids 
from the N terminal was mostly well tolerated. 
Removal of the N-terminal serine and glycine 
improved nerve selective binding about 2-fold with a 
normalized average signal intensity of 2.02 ± 0.65 for 
HNP401-N-2 (Figure 5A, J, p=0.026, Student’s t-test, 
unpaired, one-tail). HNP401-N-4 has non-polar amino 
acids on its N-terminus, which reduced binding to a 
normalized average signal intensity of 0.56 ± 0.18 
(Figure 5B). Removal of non-polar amino acids, 
tryptophan and proline, restored some binding 
intensity back to levels of FAM-HNP401, with 
HNP401-N-6 (Figure 5C) and HNP401-N-8 (Figure 
5D) having normalized average nerve signal 
intensities of 1.0 ± 0.34 and 0.98 ± 0.31. The restored 
binding efficiency may be due to improved solubility 
minimizing micro-aggregation that occurs when very 
hydrophobic residues are present at the N terminus of 
a peptide. C and N terminal deletion studies of 
HNP-401 indicate the core binding domain likely 
includes PYYVVKK, with the N-terminal residues 
QVPWEE contributing to the enhanced binding 
detected with HNP401-N-2. Normalized nerve-to- 
temporalis muscle contrast for HNP401-N-2 gave a 
3-fold increase with respect to FAM-HNP401 (Figure 
5K, p=0.011, Student’s t-test, unpaired, one-tail). 
Discussion 
 Various tracer substances have long been used 
to map the connectivity in the nervous system, 
although most of them have depended on 
anterograde or retrograde tracing after local 
application [11, 12, 26, 27]. Transport of tracers is 
relatively slow, with contrast developing as dye 
moves away from the injection site [26, 27]. It is likely 
impractical to label the large areas exposed for 
surgeries by using these methods as multiple nerve 
tracts would have to be identified and independently 
labelled. There are reports of tracking retrograde 
neurovascular bundle and major pelvic ganglion with 
lipophilic dyes in rodents [4, 28]. More recently, styryl 
pyridinium dyes [13-15], aminostyryl dyes [16-18], 
oxazine 4 [19, 20], and anti-ganglioside antibodies [21] 
have been investigated in various preclinical models 
to detect motor, sensory and autonomic nerves. Dyes 
alone have no selective mechanism for nerve targeting 
but typically accumulate in the myelin. Myelin is 
known to be present in low abundance or be absent in 
autonomic nerves, which could limit the use of free 
dyes to highlight these fine but crucial nerves [29, 30]. 
 
Figure 4. HNP401 binds to fresh viable nerve from the prostate gland and median anti-brachial cutaneous human nerve. Fluorescence imaging after topical 
application of 100 µM FAM-HNP401 or FAM-NP41 on 10 µm sections on cryosectioning tape of nerve within human prostate gland, (A-B) or from median anti-brachial 
cutaneous human nerve (E-F). Nerves were imaged immediately after sectioning and application of peptide using confocal microscopy. Immunohistochemistry analysis with dual 
labelling for neurofilament antibody SMI312 (red) and DAPI-stained nuclei (blue) (C, G) and corresponding H&E staining (D, H) of a fixed section of nerve on glass slides.  
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Topical and epidural application of free dyes has been 
used to locally label nerves in animal models; 
however, these approaches may be limited in 
flexibility during human surgeries as tissue is 
removed and the field of view changes [20, 31]. 
Anti-ganglioside antibodies have specific targeting 
but have long blood half-lives, which would likely 
require injection multiple days before surgery and 
may be more likely to elicit an immune response [32, 
33]. Systemic injection of fluorescently labeled 
peptides to label nerves overcomes the major 
disadvantages of these tracers by labeling all nerves in 
the body with a single injection of peptide-dye 
conjugate. We previously reported on NP41 for 
binding rodent motor and sensory nerves and now 
demonstrate its potential application to the 
identification of fine autonomic nerves in rodent 
models. We found an average increase of 17% in 
nerve-to-non-nerve signal using fluorescence imaging 
compared to contrast obtained by white light 
reflectance. This is a significant accomplishment given 
the unmyelinated nature of these nerves and their 
ultra-fine structure. However, topical application of 
NP41 to human ex-vivo provided little contrast 
compared to muscle. To enhance highlighting of 
human nerves, we have now identified HNP401, a 
novel peptide that binds to and highlights human 
motor/sensory and autonomic nerves.  
We expect the FAM-HNP-401 or an optimized 
analog could enable clinical translation of nerve 
visualization methods for use in surgeries involving 
human patients. Fluorescently labeled HNP401 can 
bind and highlight human sural, medial antebrachial 
cutaneous, laryngeal and autonomic nerves within 
and around the prostate gland. FAM-HNP401 
showed high signal intensity and reproducible 
labelling of nerve bundles compared to its dye control 
of carboxyfluorescein. Carboxyfluorescein shows low 
signal and non-specific binding to nerve on topical 
human nerve sections. Dyes such as 
FITC-isothiocyanate cannot be used as the control as 
they will react with all nucleophilic side chains of 
proteins exposed by cross-sectioning in unfixed 
tissue. Additionally, FITC-dextran, although clinically 
used, is not a viable control for our experiments as it 
labels vasculature including micro blood vessels deep 
within the nerve cross section and is a marker for 
nerve injury and neuropathic pain [34]. In addition, its 
large size affects the pharmacokinetic profile of the 
dye. FAM-HNP401 consistently gave 10-fold higher 
 
Figure 5. Comparison of truncated sequences to determine binding efficiency. Representative fluorescence images of unfixed human sural nerve that were treated 
topically with 100 µMof FAM-labelled N-2 (A), N-4 (B), N-6 (C), N-8 (D), C-2 (E), C-4 (F), C-6 (G), C-8 (H) or HNP401 (I). Due to poor solubility, C-6 had a final 
concentration of a73 µM and C-8 had a final concentration of b80.6 µM for topical tests. (J) Comparison of signal intensity of peptides normalized to FAM-HNP401 were made 
to test for improved binding. (K) Normalized sural nerve to temporalis muscle contrast was determined for FAM-HNP401 and FAM-HNP401-N-2 (Student t-test, unpaired, 
one-tail, p=0.011). 
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signal for binding human nerve compared to our 
previously identified FAM-NP41 peptide-dye 
conjugate. Higher signal intensity is an advantage for 
real-time imaging requiring short exposure times. 
HNP401 also showed a 3-fold contrast for nerve to 
muscle on topical sections in human ex-vivo tissue. 
FAM-HNP401 has a blood clearance profile similar to 
NP41 in mice [22]. FAM-HNP401 binds to myelinated 
and unmyelinated nerves. SMI312 antibody, which 
labels neurofilament, did not colocalized with 
FAM-HNP401 staining, demonstrating that 
FAM-HMP401 does not bind axons, but preferentially 
binds the perineurium, and therefore may be less 
likely to affect nerve conductivity. It is this staining 
pattern that leads us to believe HNP401-FAM is 
binding structural protein(s) in the perineurium. Polar 
amino acids at the C terminus appear to be needed for 
both solubility and binding as removal of either 
caused the peptide to become significantly less 
soluble or show decreased binding affinity to nerves. 
Removal of 2 amino acids on the N terminus 
increased nerve binding but further deletions 
negatively affected both solubility and binding. 
Attaching solubilizing groups like short pegs may 
restore binding to truncated variants. 
In our initial studies, nerve-highlighting peptide 
HNP401 was coupled to a fairly short wavelength 
fluorescein derivative to make it compatible with dual 
nerve/tumor imaging using Cy5/Cy7 ratiometric 
activatable cell-penetrating peptides, which are 
currently in phase II clinical testing for detection of 
cancer (NCT03113825). Longer wavelength IR or 
near-IR dyes such as indocyanine green (ICG) or 
IRdye800 would potentially allow nerves to be 
imaged deeper below the surface in surgically 
exposed tissue after attachment to HNP-401. Free 
oxazine 4 has also been recently used to highlight 
nerves in preclinical models, and targeting could be 
enhanced by coupling to targeting peptides like 
HNP401. Although our preferred method of 
application is systemic, topical application is an 
option with some procedures. Such topical 
application of dye to the exposed surface followed by 
a washing to remove unbound dye has been used to 
image nerves in animal models [20]. Dyes such as 
4-di-2-asp have also been used for topical application 
to nerves, but it has the disadvantage of being toxic to 
nerves due to its binding to mitochondria in nerve 
terminals [35]. Antibodies can be applied 
intravenously or topically and have some advantages 
including high affinity and a defined binding target; 
however as reported with the anti-ganglioside 
antibody, they require long circulation times for 
accumulation and washout to develop optimal nerve 
contrast.  
In in vivo rodent studies, we found that 
peripheral motor and sensory nerves can be labeled in 
mice at a dose of 150 nmol FAM-NP41, which would 
easily scale to human dosing [36, 37]. Autonomic 
nerve labeling required a significantly higher dose in 
mice (600 nmol), so higher affinity peptides like 
HNP401 or improved variants may be required for 
advancement to clinical dosing. Interestingly, 
although higher dosing was required to visualize very 
small autonomic nerve in rodents (as small as 50 µm), 
labeling of significantly larger human prostate nerves 
(~750 µm) may be accomplished at a significantly 
reduced dose. Consistent with the conclusion that 
larger nerves can be highlighted with a lower dose, 
we were able to visualize nerves in rat prostate with a 
40% dose NP41. Neither NP41 nor HNP401 
permanently or covalently bind to nerve bundles as 
they both washed out with little remaining signal 
after 24 h. Structural proteins including laminins 421 
and 211 have been identified as the binding targets for 
NP41[25]. While the binding targets for HNP401 have 
yet to be determined, imaging data shows a 
non-axonal binding pattern similar to NP41, 
indicating it may also bind structural nerve proteins. 
One significant characteristic of HNP401 compared to 
lipophilic dyes is that it does not require the presence 
of myelin and we have shown that it can bind and 
highlight the neurovascular bundle as well as the 
cavernosal nerve within the prostate. These nerves are 
important in urological applications and do not have 
high levels of myelination [29, 30]. We anticipate that 
preservation of nerves in this context represents one 
of the most urgent unmet clinical needs [38] for nerve 
imaging technology. The ability of FAM-HNP401 to 
highlight these nerves represents a significant 
advantage over competing nerve-binding agents that 
are selective for myelin [39] and incorporate into 
axons [21].  
In addition to carrying dyes to highlight nerves 
for image-guided surgery, we envision the use of 
short nerve-binding peptides as carriers for 
therapeutics agents. Such conjugated systems might 
facilitate repair/regeneration of damaged nerves both 
in the periphery nervous system and in the spinal 
cord. The small size of nerve peptides like HNP401 
also make them ideal for coating nanoparticles or 
dendrimers for delivering large payloads of drugs or 
imaging agents to the nervous system. NP41 serves as 
a useful agent for tracking mouse nerve in live 
animals requiring rapid binding and clearance of the 
agent. However, we expect that HNP401 or an 
optimized variant could have tremendous impact on 
patient outcomes by helping surgeons identify nerves 
prior to their exposure during surgery. The high 
signal intensity of HNP401 nerve highlighting should 
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enable nerve visualization with less sensitive 
wide-field imaging systems used during open surgery 
to reduce inadvertent nerve injury and post-surgical 
patient morbidity.  
Methods 
Probe synthesis  
FAM-NP41 was synthesized as previously 
described [22]. A Prelude peptide synthesizer and 
standard Fmoc solid phase peptide synthesis was 
used to generate peptides with sequences acetyl- 
SGQVPWEEPYYVVKKSSGGCCONH2 [HNP401], 
acetyl-WEYHYVDLNWTSQHPQGGC-CONH2 
[HNP402], and acetyl-DLPDIIWDFNWETAGGC- 
CONH2 [HNP403]. Carboxyfluorescein was 
conjugated to the C-terminal cysteine using 
5-fluorescein-maleimide [Anaspec] in the presence of 
N-methylmorpholine in DMSO. Peptides were 
purified on Agilent LCMS using a Phenomenex 5 μm 
C18 Luna with mass and purity > 95% confirmed by 
LC-MS. Truncated HNP401 peptides as listed in 
Table S1 were synthesized and purified using the 
same configuration and method described above.  
Animals  
Wild-type male SKH1 mice (Charles River, 
Wilmington, MA) weighing 20-30 g were used for 
testing of peptide-dye conjugates. Male Sprague- 
Dawley rats weighing 100 to 250 g were used for in 
vivo testing of dye conjugates with the dose adjusted 
based on animal size. Protocols for the use of animals 
were approved by the Institutional Animal Care and 
Use Committee at University of California San Diego 
(Protocol number S05536). 
In vivo imaging 
Following anesthesia with intra-peritoneal 
injection of ketamine (80 mg/kg) and midazolam (40 
mg/kg), FAM-NP41 or its variants were administered 
into mice retro-orbitally. After a washout period of 2-4 
h, the animals were anesthetized with ketamine (50 
mg/mL) and xylazine (20 mg/mL). The bladder and 
prostate were exposed through a midline abdominal 
incision. The autonomic nerve along the cavernosal 
vessel in the prostate was imaged and recorded using 
a custom-made surgical imaging system. This system 
is modified from an Olympus MVX10 scope capable 
of high-resolution fluorescence, RGB reflectance and 
real-time overlay with zoom from 0.6 to 5.7 cm 
field-of-view. ImageJ was used for quantitative 
analysis of nerve contrast for each peptide-dye 
conjugate tested. Images of autonomic nerve in 
prostate were selected from the recorded files and 
magnified 300-400% prior to selection of the ROI and 
measurement. Nerves and adjacent non-nerve tissue 
ROIs were hand-selected using the polygonal 
selection tool at the same location from both 
reflectance and fluorescence images. The mean and 
standard deviation of the pixel intensities within the 
selected areas were compared for nerves (mean = In, 
SD = σn) and adjacent background tissue (mean = Ib, 
SD = σb). Nerve-to-non-nerve contrast was calculated 
after background subtraction with the formula |In 
–Ib| / (σn2 + σm2)0.5. For imaging the nerves in the 
prostate gland of male rats, peptide-dye conjugate 
were injected retro-orbitally. FAM-HNP401 was 
injected at a concentration of 13 mg/kg followed by 
imaging after 15 min, or, alternatively, a dose of 52 
mg/kg was used with imaging after 3 h. Live animal 
surgery was performed under a ketamine-xylazine 
cocktail according to IACUC protocol. Sterile 
technique was used to expose the prostate; the 
bladder was drained with a small syringe and 
sutured. The surgical field was washed with sterile 
saline prior to imaging. Mann-Whitney test was used 
to analyze data for both mice and rats to compare 
nerve intensity and nerve-to-non-nerve contrast 
between white light reflectance and fluorescence 
images.  
Confocal imaging parameters 
Confocal data for Figure 2 was acquired for 10 
µm sections on glass using a 488 nm laser line and 10x 
magnification 0.45 NA air objective lens. The gain was 
set to 50, power was 0.5% of the laser power, pixel 
dwell time was 1.2 µs, aperture size was 1.2 µm, pixel 
size was 0.26 µm/px, and image size was 2k × 2k. We 
used the Nyquist feature and acquired images as tiles 
to get maximum resolution.  
Confocal data for Figure 4A and B was acquired 
for 10 µm sections on glass using a 488 nm laser line 
and 10x magnification 0.45 NA air objective lens. The 
gain was set to 40, power was 3% of the laser power, 
pixel dwell time was 1.2 µs, aperture size was 1.2 µm, 
pixel size was 0.26 µm/px, and image size was 2k × 
2k. We used the Nyquist feature and acquired images 
as tiles to get maximum resolution.  
Confocal data for Figure 4E and F was acquired 
for 10 µm sections on glass using a 488 nm laser line 
and 10x magnification 0.45 NA air objective lens. The 
gain was set to 40, power was 1% of the laser power, 
pixel dwell time was 1.2 µs, aperture size was 1.2 µm, 
pixel size was 0.3 µm/px, and image size was 2k × 2k. 
Nyquist feature was not used. 
Confocal data for SMI312 neurofilament 
antibody and Dapi staining were imaged at 10x 
magnification, 0.45 NA air objective lens with gain of 
50, power of 5% of laser power for 405 nm laser line 
and gain of 100, power of 50% of laser power for 640 
nm laser line. We used a pixel dwell was 3.2 µs, 
 Theranostics 2018, Vol. 8, Issue 15 
 
 
http://www.thno.org 
4235 
aperture size was 1.2 µm and image size was 2k by 2k 
per tile resulting in a pixel size of 0.29 µm/px. We 
used the Nyquist feature and acquired images as tiles 
to get maximum resolution. Confocal data for Figure 
S6 was acquired for 10 µm sections on glass using a 
488 nm laser line and 10x magnification 0.45 NA air 
objective lens. The gain was set to 40, power was 3% 
of the laser power, pixel dwell time was 2.4 µs, 
aperture size was 1.2 µm, pixel size was 0.3 µm/px, 
and image size was 2k × 2k. Nyquist feature was not 
used. 
Dose response data set of FAM-HNP401 on 
human nerve tissue (Figure S5A-E)was acquired for 
10 µm sections on glass using a 488 nm laser line and 
10x magnification 0.45 NA air objective lens. The gain 
was set to 40, power was 3% of the laser power, pixel 
dwell time was 1.2 µs, aperture size was 1.1 µm, pixel 
size was 0.3 µm/px, and image size was 2k × 2k. 
Nyquist feature was not used. 
Confocal data for Figure S9 was acquired for 10 
µm sections on glass using a 488 nm laser line and 25x 
magnification 1.10 NA water immersion lens. The 
gain was set to 40, power was 3% of the laser power, 
pixel dwell time was 2.2 µs, aperture size was 1.2 µm, 
pixel size was 0.11 µm/px, and image size was 2k × 
2k. 
Phage display 
Phage display was done using a 
custom-synthesized m13 phage library (diversity 
~109) expressing 16 random amino acids on the 
N-terminus of gIII (Creative Biolabs). The phage 
library was processed through selections for binding 
to freshly resected or frozen human nerves, as was 
similarly described for the identification of NP41 that 
bound mouse nerves [22]. The library was processed 
through up to 6 binding and washing cycles. Prior to 
positive selection, phage were counter-selected for 
high-affinity muscle and fat tissue binding by 
pre-adsorbing the tissues with the library. For positive 
selection, phage libraries were mixed directly with 
human sural nerve tissue and incubated for up to 2 h 
at 4 °C. Following incubation, tissue phage mixtures 
were centrifuged and washed with PBS. Tissue pellets 
with bound phage were then homogenized, mixed 
with TG1 bacteria and plated on LB agar plates. 
Colonies were counted to determine titer followed by 
selecting single colonies for DNA preparation and 
sequencing. After each round of selection, phage were 
pooled and amplified for iterative selection. Phage 
that were bound at each round were sequenced and 
repeats noted. Duplicate phage as shown in the 
results were identified after 5 and 6 rounds of 
selection.  
Topical application on tissue sections and 
imaging 
Human sural nerve, antebrachial nerve and 
laryngeal nerve and temporalis muscle were obtained 
under IRB protocol number 130837 for Dr. Quyen 
Nguyen. Human peripheral nerves (typically sural) 
were obtained from patients undergoing nerve 
resection procedures. Human nerves from the 
prostate gland of two patients were acquired under 
Moores Cancer Centre Biorepository IRB protocol 
number 090401. Tissues were sectioned and mounted 
on glass slides or Cryojane tape. Tissue sections were 
placed in a humidifier chamber for 30 min before 
application of the peptide solution. Peptides were 
diluted to the appropriate concentration in 0.5X HBSS 
prior to topical application. 50 µL of peptide solution 
of known concentration (1 µM to 375 µM) was applied 
to 10 µm nerve sections on tape or slides and 
incubated for 30 min in a humidifier chamber. After 
incubation with peptide nerve, sections were washed 
twice with 0.5X HBSS and once with 1X PBS. A 
cover-slip was applied and slides were imaged 
immediately on either a Zeiss Lumar dissecting scope 
or a Nikon A1 confocal microscope. For confocal 
imaging, tissue sections of 10 µm thickness were 
imaged with a 488 nm laser excitation and 
515nm/25nm band pass emission filter using a 10x air 
objective at a 0.26 µm/pixel resolution. For 
immunohistochemistry the confocal images were 
acquired with a 20x air objective at a resolution of 0.4 
µm/pixel.  
Image analysis 
Image J was used to analyze and compare 
images acquired using the confocal microscope and 
the Lumar dissecting scope. For each experimental set 
where probes were compared, we kept the acquisition 
parameters identical so as to directly compare the 
data obtained. During the experiment, it is clear that 
FAM-HNP401 had the brightest signal in our topical 
application experiments. All raw image files for a 
given experimental cohort were loaded at the same 
time into Image J as 16-bit tiff images. We then 
levelled the images for tissue treated with 
FAM-HNP401. Once these levels were set, the settings 
were propagated to all images in one step using 
Image J. The brightest image was set as the 
benchmark for all other images in the cohort to avoid 
saturating when the leveling was propagated. For 
quantifying the images, regions-of-interest (ROI) were 
drawn and the signal counts measured in image J. For 
Figure 5, even though FAM-HNP401-N-2 was the 
brightest, for consistency we choose FAM-HNP401 to 
level and normalize signal counts. 
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Immunofluorescence of autonomic nerves 
from rat prostate 
Suspect unmyelinated nerve tissue was taken 
from the prostate gland of male rats after in vivo 
intravenous injection of TAMRA-NP41 (0.5 µmol or 
11.3 mg/kg for 100 g rats) visualized on a 
custom-made surgical fluorescence imaging system 
based on an Olympus dissecting microscope. 5 µm 
cryosections of the tissue were generated using a 
Leica Cryostat and mounted on Cryojane tape. Tissue 
sections were fixed for 10 min with 4% 
para-formaldehyde in 1X PBS followed by a 1X PBS 
rinse. A 1:2000 dilution of monoclonal antibody 
against TAMRA (Thermofisher Scientific Cat. No. 
MA1-041) or polyclonal antibody against tyrosine 
hydroxylase (Cell Signaling Technologies Prod. No. 
2792S) in 10 % goat serum in PBS was applied (20 µL 
per section) and incubated overnight at room 
temperature followed by a 1X PBS wash. A 1:500 
dilution of biotinylated anti-mouse secondary 
antibody was applied in 10% goat serum in PBS to 
sections for 2 h followed by a 1X PBS wash. Vector 
RTU (avidin biotin complex) or Alexa 405 streptavidin 
was applied for 1 h followed by a 1X PBS wash. Tissue 
was wet-mounted on slides with 1X PBS. Confocal 
images were acquired with a 20x air objective at 
resolution of 0.4 µm/pixel. 
Immunofluorescence for neurofilament 
Fresh viable human nerve tissue was obtained 
from prostatectomy and frozen in OCT blocks. 10 µm 
cryosections of tissue were mounted on glass True 
Bond slides. Hydrophobic barrier pen was applied to 
the glass around each section. Tissue sections were 
fixed using 2% paraformaldehyde prepared in 1X PBS 
and washed 4 times with 1X PBS. 100 µL of blocking 
buffer (0.01% Triton X solution, 1% BSA in 10% 
normal goat serum (Life technologies 50062Z)) was 
applied for 30 min to each tissue section. The tissue 
was then washed 4 times with 1X PBS and a 1:1000 
dilution of neurofilament SMI312 antibody (Biolegend 
Cat. No. 837904) was applied to the tissue for 
overnight incubation at 4 °C. Tissues were washed 6 
times with PBST. A 1:1000 dilution of anti-mouse 
secondary antibody AlexaFluor 555 was applied to 
the sections for 2 h at 4 °C followed by washing with 
1X PBS. Prolong Gold Anti-fade reagent with DAPI 
(Life Technologies P36931) was added prior to cover 
slipping and imaging.  
H&E staining protocol 
Tissue sections were fixed for 1 min in 1:1 10% 
buffered formaldehyde and 200 proof ethanol. Slides 
were then washed with water and immersed in 
hematoxylin stain for 2 min. Slides were then washed 
with distilled water and immersed in bluing solution 
for 30 s. Slides were washed with distilled water and 
immersed in eosin solution for 1 min followed by 
washing with distilled water. Slides were sequentially 
dipped in 50%, 95% and 100% ethanol to remove 
water. Slides were air dried and dipped in citrisolv 
before mounting a cover-slip with non-xylene 
mounting solution and imaging on a Hamamatsu 
Nanozoomer using bright-field imaging at 20x 
magnification.  
Blood clearance for HNP401-FAM 
Five 8-week-old SKH male mice were injected 
intravenously with 100 nmol (10.75 mg/kg for 25 g 
mice) of FAM-HNP401 in 100 µL of sterile water. Prior 
to blood draw, mice were anesthetized with a 1:1 
cocktail of ketamine: midazolam. Tail pricks were 
performed at 1 min, 10 min, 20 min, 30 min, 1 h, and 2 
h after injection to collect 5 µL whole blood, which 
was dissolved in 100 µL Agilent ICP-MS tuning 
buffer. Samples were centrifuged and equal volumes 
of supernatants were analyzed using a Tecan 
fluorescence plate reader. 
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Supplementary figures and table.  
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